Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility in a homeopathy for seasonal allergic rhinitis RCT: importance of therapeutic relationship and organizational capacity.

Frontiers in allergy·2026
Same author

dVP_FAM-development and evaluation of a transsectoral digital care platform for individuals with familial cancer risks: study protocol for a multi-centre, cluster-randomised, mixed-methods study.

Trials·2025
Same author

Reliability of a novel point of care device for monitoring diabetic peripheral neuropathy.

Scientific reports·2023
Same author

Homeopathy for seasonal allergic rhinitis: rationale, design and methods of the three-armed randomized controlled HOMEOSAR trial.

BMC complementary medicine and therapies·2022
Same author

Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP).

Infection·2021
Same author

Acupuncture in diabetic peripheral neuropathy-protocol for the randomized, multicenter ACUDPN trial.

Trials·2021
Same journal

[Advancing cardiovascular prevention : Evidence-based design of healthy and sustainable food environments].

Herz·2026
Same journal

[Effects of air pollution on cardiovascular health].

Herz·2026
Same journal

[Heart and climate].

Herz·2026
Same journal

Multidimensional psychosocial screening in routine cardiac care: preliminary findings from a cross-sectional survey.

Herz·2026
Same journal

[Noise and the heart].

Herz·2026
Same journal

[The cardiovascular exposome: areas of action for prevention and practical cardiology].

Herz·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Sequencing of mRNA from Whole Blood using Nanopore Sequencing
11:26

Sequencing of mRNA from Whole Blood using Nanopore Sequencing

Published on: June 3, 2019

[Second-generation DES : New, but also cost-effective?].

F Müller-Riemenschneider1, T Reinhold, S N Willich

  • 1Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Charité - Universitätsmedizin Berlin, Deutschland. falk.mueller-riemenschneider@charite.de

Herz
|April 22, 2011
PubMed
Summary
This summary is machine-generated.

Second-generation drug-eluting stents (DES) show limited cost-effectiveness compared to bare metal stents (BMS). More research is needed, especially in Germany, to determine the value of newer DES technologies.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Open-Source Miniature Fluorimeter to Monitor Real-Time Isothermal Nucleic Acid Amplification Reactions in Resource-Limited Settings
09:36

Open-Source Miniature Fluorimeter to Monitor Real-Time Isothermal Nucleic Acid Amplification Reactions in Resource-Limited Settings

Published on: February 3, 2021

Related Experiment Videos

Last Updated: Jun 2, 2026

Sequencing of mRNA from Whole Blood using Nanopore Sequencing
11:26

Sequencing of mRNA from Whole Blood using Nanopore Sequencing

Published on: June 3, 2019

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Open-Source Miniature Fluorimeter to Monitor Real-Time Isothermal Nucleic Acid Amplification Reactions in Resource-Limited Settings
09:36

Open-Source Miniature Fluorimeter to Monitor Real-Time Isothermal Nucleic Acid Amplification Reactions in Resource-Limited Settings

Published on: February 3, 2021

Area of Science:

  • Cardiovascular Medicine
  • Health Economics
  • Interventional Cardiology

Background:

  • Second-generation drug-eluting stents (DES) represent advancements over bare metal stents (BMS) and first-generation DES.
  • Assessing the economic value of these newer devices is crucial for healthcare systems.

Purpose of the Study:

  • To review the cost-effectiveness of second-generation DES in comparison to BMS and first-generation DES.
  • To identify gaps in the existing economic evidence for second-generation DES.

Main Methods:

  • A structured literature review of MEDLINE was performed up to December 2010.
  • Studies were selected based on pre-specified criteria, focusing on cost-effectiveness of second-generation DES.
  • Data on clinical, economic, and cost-effectiveness outcomes were extracted and summarized.

Main Results:

  • Only five studies met the selection criteria, primarily from the US, UK, and Spain.
  • Three studies evaluated the zotarolimus-coated Endeavor stent (ZES) versus BMS; two compared ZES to first-generation DES.
  • Limited evidence suggests second-generation DES may not be cost-effective compared to BMS, with no conclusive data against first-generation DES.

Conclusions:

  • There is a significant lack of cost-effectiveness evidence for second-generation DES, particularly within the German healthcare system.
  • Current evidence indicates second-generation DES may not be cost-effective compared to BMS.
  • Further methodologically rigorous economic evaluations are urgently needed, especially for the Everolimus-coated Xience V stent.